Thank you to the speakers and to all who tuned into our annual flagship Summit event. Be sure to catch up with coverage from the event, and learn more about all of our upcoming Summits.
A multi-year pandemic has brought no end of trials, but also plenty of triumphs. Come for a silo-breaking and solution-focused discussion of the most important topics in health care with some of the industry’s greatest minds. Join virtually or in person in Boston. Whichever option you choose, this two-day summit will give you unique insights into the most important topics in biotech, medicine, and policy.
Get tickets
Learn from our speakers, get their expert insights.
Chairman & CEO, Pfizer
Vice Chair, Clinton Foundation
Virtual Speaker
Director of the National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institutes of Health
Executive Chairman, Merck; Chairman of Health Assurance Initiatives, General Catalyst
Virtual Speaker
Coordinator of COVID-19 Response, White House COVID-19 Response Team
Chief Executive Officer and President, Vertex
Professor and Director, The Merkin Institute of Transformative Technologies in Healthcare; Vice-Chair, Broad Institute of MIT and Harvard; Professor of the Natural Sciences, Harvard University; Howard Hughes Medical Institute (HHMI) Investigator
Associate Professor of Medicine, Columbia University
Co-Founder and CEO, Apriori Bio; Origination partner, Flagship Pioneering
Executive Vice President, Global Research, and Chief Scientific Officer, Vertex
Sponsor Speaker
Executive Vice President of Research and Development, Allogene Therapeutics
Sponsor Speaker
President & Chief Executive Officer, UroGen Pharma
Chief Executive Officer and Founder, Altos Labs
Chief Scientific Officer and Chief Medical Officer, Verve Therapeutics
Sponsor Speaker
Chief Commercial Officer, Immune Medicine, Adaptive Biotechnologies
OB/GYN, Abortion Provider, and Subspecialist in Complex Family Planning in New Jersey and Board Chair of Physicians for Reproductive Health
Writer, Playwright, ALS Advocate
Sponsor Speaker
President of City of Hope National Medical Center; Deana and Steve Campbell Physician-in-Chief Distinguished Chair
HHMI Hanna H. Gray Postdoctoral Fellow, Stowers Institute for Medical Research
Director, Altos Labs San Diego Institute of Science
Sponsor Speaker
Co-CEO, Medidata; President, Acorn AI
Sponsor Speaker
Vice President, Drug Substance Technologies, Amgen
Executive Director, Translational Research Institute for Space Health
Co-Founder, The Light Collective
Sponsor Speaker
Chief Scientific Officer, The University of Texas MD Anderson Cancer Center
Principal, Florence Healthcare; Cystic Fibrosis Patient Advocate
Director, UCSF Breast Care Center
Author and advocate
Sponsor Speaker
Vice President and Chief Diversity Officer, Genentech
Singer-songwriter and spinal muscular atrophy advocate
Scientist and Former Head of Pfizer’s Vaccine Research and Development
Assistant Dean, Office for Diversity Inclusion and Community Partnership; Associate Director and Advisor, Castle Society, Harvard Medical School
Professor of Genomics, Physiology, and Biophysics, Weill Cornell Medicine
Head of Development, Infectious Diseases, Moderna
Cancer Patient and Founder, Patients For Affordable Drugs
Chief Executive Officer, Cerebral
Deputy assistant to the president and deputy director for science and society in the White House Office of Science and Technology Policy
Student in the Department of Immunobiology, Yale School of Medicine
Founder, We Got Us; M.D./MPP Candidate ‘24, Harvard Medical School, Harvard Kennedy School
Sponsor Speaker
Vice President and Head of the Center for Health Equity and Patient Affairs, Takeda
President and CEO, Relay Therapeutics
Activist and organizer for reproductive rights
Virtual Speaker
Chair and Chief Executive Officer, Eli Lilly and Company
Co-Founder, Women of Color Wellness Alliance
Sponsor Speaker
Senior Vice President of Global Biometrics and Data Sciences, Bristol Myers Squibb
Chief Medical Officer, Maven Clinic
Astronaut, Artist, & Founding Director, Space for Art Foundation
Emergency medicine physician, writer, educator, and advocate, Yale New Haven Health
Sponsor Speaker
President and Chief Executive Officer, PhRMA
Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health
M.D.- Ph.D. candidate, Johns Hopkins School of Medicine
Breakout Speaker
Senior Vice President, Real World Data and Analytics, Optum Life Sciences
Breakout Speaker
Executive Director, LabCentral Ignite
Breakout Speaker
Director of the Center for Public Health Practice and Professional Development, American Public Health Association (APHA)
Breakout Speaker
Vice President, Client Solutions, Real World Data, Optum Life Sciences
Breakout Speaker
Global Managing Partner, Health and Wellness, Zeno Group
Breakout Speaker
Chief Medical Officer, Foundation Medicine
Breakout Speaker
Associate Professor of Medicine, Division of Hematology-Oncology Ingram Associate Professor of Cancer Research Co-Leader, Translational Research & Interventional Oncology Program Vanderbilt
Breakout Speaker
Assistant Professor of Neurology at Harvard Medical School; Assistant Neurologist at Massachusetts General Hospital; Director of Neurology Community Health Diversity and Inclusion at Massachusetts General Hospital
Breakout Speaker
Vice President, Medical Affairs, Foundation Medicine
Breakout Speaker
President, Center for Medicine in the Public Interest
Breakout Speaker
President and Chief Executive Officer, National Minority Quality Forum (NMQF)
Breakout Speaker
Chief Medical Officer, Biogen
Breakout Speaker
Founder, Stupid Cancer; CEO and Co-Founder, Offscrip Health
STAT Moderator
Senior Writer, Infectious Diseases, STAT
STAT Moderator
Editorial Director, STAT
STAT Moderator
Cancer Reporter, STAT
STAT Moderator
Washington Correspondent, STAT
STAT Moderator
Biotech Startups and Venture Capital Reporter, STAT
STAT Moderator
Addiction Reporter, STAT
STAT Moderator
Senior Writer, Biotech, STAT
STAT Moderator
National Biotech Correspondent, STAT
STAT Moderator
CEO, Boston Globe Media Partners
STAT Moderator
Business of Health Care Reporter, STAT
STAT Moderator
Senior Writer, Medicine; Editorial Director of Events, STAT
STAT Moderator
General Assignment Reporter, STAT
STAT Moderator
National Science Correspondent, STAT
STAT Moderator
Science Writer, STAT
STAT Moderator
Washington Correspondent, STAT
STAT Moderator
Bay Area Correspondent, STAT
STAT Moderator
General Assignment Reporter; Associate Editorial Director Of Events, STAT
STAT Moderator
Senior News Editor, STAT
STAT Moderator
West Coast Biotech & Life Sciences Reporter, STAT
From the future of CRISPR to the health impacts of a journey to Mars, there’s much to explore during this year’s program. Get your ticket to be a part of these conversation.
Rapid Covid-19 testing is required for all STAT Summit attendees; breakfast will be available for all attendees upon test completion.
Starting with CRISPR and continuing into base editing, the ability of scientists to change DNA continues to increase. Come here for insights from one of the biggest drivers behind this new technology.
The White House’s Covid coordinator joins the STAT Summit for a session on where we are with the pandemic, what we face in the near-term and the future of vaccines.
To conquer cancer, we need accessible innovation. But CAR T cell therapy, made from a patient’s own cells, is difficult to get to all the patients who need it. Hear how City of Hope is bringing the latest scientific advances in cellular immunotherapy to more patients across the country.
The Office of Science, Technology and Policy plays a key role in major policy decisions, including those about the pandemic. The thoughts of one of its leaders after an eventful year.
The STAT Wunderkinds have tremendous potential to improve health and medicine, and our future success depends on inspiring and guiding this new generation of researchers. With intentional and strategic investments in research, we look forward to their meaningful impacts for humanity.
Hear from the brightest young minds in science as members of this year’s newly minted class of STAT Wunderkinds take the Summit stage.
The power of immune receptor data allows us to translate the massively diverse genetic code of the adaptive immune system to improve early disease detection and develop transformative therapeutics that will save patient lives.
Vertex Pharmaceuticals, one of the biggest and most successful companies in biotech, has changed the way that cystic fibrosis is treated. Now it is aiming to take on chronic pain, type 1 diabetes, and kidney disease.
Tony Fauci has announced that he will retire in December. He’ll beam in to talk with the nation’s premier infectious disease reporter about what’s next for him and for America.
The Inflation Reduction Act was signed into law. In its wake, barriers to health care continue. And the law will have a lasting effect on innovation. We’ll discuss the IRA’s impact on access and affordability, missed opportunities to fix what’s broken in the system, and ideas for solving these issues.
Altos Labs raised eyebrows with a massive fundraising and a plan to create medicines that work by regenerating bodies that are deteriorating with age. The new company’s CEO and one of its top scientists sit down with STAT to answer questions about what it is they’re building and why they think you should believe this big idea will work.
Bristol Myers Squibb aims to address the biggest questions in biology and medicine – and help patients. How? With artificial intelligence that increases the predictive power of clinical trials, with our own research, and through partnerships to create new technologies. Hear the details.
Patients need and deserve more equitable care. But creating a new health care ecosystem requires creating the right career opportunities for those working in the life sciences. Join us to learn about innovative efforts to create a more diverse talent pool and a better health care system.
Achieving health literacy requires we communicate with people — not patients.
The past twenty years have seen an unprecedented acceleration in advances against cancer. But this disease is still one of the leading causes of death in the developed world. How do we push this progress into overdrive?
When it comes to improving the probability of success in clinical trials, simply digitizing data is not enough to reduce cost and development time. Here is how to use technology to speed research.
Nothing has cushioned the blow of this once-a-century pandemic more than the Covid vaccines. Hear from two key scientists who led the clinical research at Moderna and Pfizer.
The Supreme Court ruling to overturn Roe V. Wade could have a huge impact on Women’s Health beyond abortion. How can we minimize the downside?
Rapid Covid-19 testing is required for all STAT Summit attendees; breakfast will be available for all attendees upon test completion. Attendees that received a negative test on day one of the STAT Summit will not be asked to re-test on day two.
Pfizer’s response to the pandemic transformed both the company’s finances and its reputation. As vaccine and antiviral sales begin to wane, what is next for the storied drugmaker?
Black residents often leave or are terminated from training programs, leaving specialties like neurosurgery, dermatology, and plastic surgery with a shocking lack of diversity. How can we fix this?
Two trenchant speakers with different ideas about the links between drug pricing and innovation discuss the future of the biomedical industry and the need to ensure that patients can get access to and afford new treatments.
The global market for CAR T therapies is expected to expand dramatically as patients become eligible for treatment in earlier stages of their disease, exacerbating an existing access bottleneck for patients. Allogeneic CAR T is an off-the-shelf product that breaks this bottleneck by addressing the critical limitations of autologous therapies. Leading oncologists have come together to support the advancement of an off-the-shelf option with the potential to treat more people with cancer faster, more reliably and at greater scale.
Human beings have dreams of heading to Mars and beyond. But it’s not clear they can survive the journey. Here’s a plan for fixing that.
Cerebral started with a laudable goal: making care accessible in the face of a nationwide mental health crisis and increasing health equity. The company has ended up being controversial, even facing government scrutiny. A case study in the difficulties of changing the care model.
People of color make up 40% of the US population, yet they represent less than 16% of clinical trial participants. Unfortunately, myths and misinformation about the costs of diversifying clinical research are preventing people with serious and life-threatening diseases from getting a chance to receive investigational medicines.
Since retiring as CEO of Merck, Ken Frazier has been viewing health equity first hand by running a clinic in his old Philadelphia neighborhood. He’ll bring new insights and ideas for the future.
Hopes for new treatments for obesity, Alzheimer’s, and cancer have made Lilly among the planet’s most valuable drug firms. What does the company need to do to beat expectations, and what does that mean for the larger pharmaceutical industry?
Hear pitches from three companies with potentially revolutionary technologies. Could these companies change the world?
Amgen is committed to ensuring its medicines are available for “every patient, every time.” Process development and manufacturing expertise enables the delivery of more therapies of increasing sophistication faster than ever to reliably supply medicines to patients around the world.
Nora Volkow’s research has changed the way scientists think about addiction – but can science make a difference as U.S. drug overdose deaths surpass 107,000 per year?
For more than 240 years Takeda has asked the same question “How can we do more for our patients?” A look at different ways pharma and healthcare systems can co-create with communities to provide sustainable, equitable access to care for all patients.
Too often, cancer care is determined more by a person’s zip code than their genetic code. Diagnostic testing has the potential to connect people living with cancer with the best treatment option for them. Hear about how we can either reduce gaps in care or widen them, depending on how we work together.
“Real world” data (RWD) from insurance claims, electronic health records, and integrated sources provide life science companies with a vast amount of additional detail – beyond clinical trials – to drive insight and enable decision making. However, the ability to employ real world data is often stymied by an array of challenges – many of which are addressable by executives. Come to learn how to maximize the ROI of RWD.
In honor of National Bladder Health Month, we’ll discuss a new treatment paradigm for non-muscle invasive bladder cancer and the potential shift from surgical care and disease management to therapeutic ablation, and how UroGen is fundamentally changing the way urologic and specialty cancers are treated.
Join your favorite podcasters for a live recording of STAT’s weekly podcast, “The Readout LOUD.” They’ll be discussing the latest breaking biotech news and recapping their favorite STAT Summit moments.
You can participate in the virtual programming from the comfort of your own computer or be a part of the program in Boston at the Renaissance Boston Waterfront Hotel.
© Mapbox © OpenStreetMap
Sign up today for summit news and updates
Contact us at [email protected] with any questions or to register as press
